In human medicine, hyperhomocysteinemia is a well-known cardiovascular risk factor, which has been associated with the progression of renal failure. In human dialysis patients, hyperhomocysteinemia is considered a frequent condition, which can be corrected by standard haemodialysis only partially. In veterinary medicine, blood homocysteine resulted increased in dogs with chronic kidney disease (CKD) of different etiologies. The aim of the present study was to evaluate plasma homocysteine in a group of dogs with acute kidney injury (AKI) or acute on chronic kidney disease (AKI/CKD) treated with intermittent haemodialysis (IHD). Fifty dogs treated with IHD at the Service of Hemodialysis and Blood Purification (SEPEV) of the University of Pisa between September 2015 and July 2017 were included. Plasma concentrations of homocysteine pre and post dialysis were obtained, by using HPLC plasma method with the Homocysteine kit in plasma/serum (CHROMSYSTEMS ®, Diagnostics by HPLC & LC-MS/MS). Data were statistically analysed through GraphPad prism ®7, and a p-value <0.05 was considered significant. Twenty-three males and 27 females of different breed, age and body weight were included. 24/50 (48%) dogs were diagnosed as AKI, while 13/50 (26%) were diagnosed as AKI/CKD. There was no statistically significant difference between pre and post treatment homocysteine values in AKI and AKI/CKD dogs. Mean post-treatment homocysteine concentrations showed a non significant trend to reduce, compared to pre-treatment concentrations. No statistically significant difference in homocysteine concentration was found between AKI and AKI/CKD. No statistically significant correlation between plasma homocysteine and creatinine was found. No differences were also found in homocysteine concentration between survived and not survived dogs. In conclusion homocysteine seem not to change between AKI and AKI/CKD dogs, and not to be significantly affected by the haemodialysis treatment. Further studies with larger number of dogs and complete cardiological evaluation should be encouraged.
PLASMA LEVELS OF HOMOCYSTEINE IN NEPHROPATIC DOGS SUBMITTED TO INTERMITTENT HAEMODIALYSIS
Ilaria Lippi
;Valentina Meucci;Veronica Marchetti;Grazia Guidi
2018-01-01
Abstract
In human medicine, hyperhomocysteinemia is a well-known cardiovascular risk factor, which has been associated with the progression of renal failure. In human dialysis patients, hyperhomocysteinemia is considered a frequent condition, which can be corrected by standard haemodialysis only partially. In veterinary medicine, blood homocysteine resulted increased in dogs with chronic kidney disease (CKD) of different etiologies. The aim of the present study was to evaluate plasma homocysteine in a group of dogs with acute kidney injury (AKI) or acute on chronic kidney disease (AKI/CKD) treated with intermittent haemodialysis (IHD). Fifty dogs treated with IHD at the Service of Hemodialysis and Blood Purification (SEPEV) of the University of Pisa between September 2015 and July 2017 were included. Plasma concentrations of homocysteine pre and post dialysis were obtained, by using HPLC plasma method with the Homocysteine kit in plasma/serum (CHROMSYSTEMS ®, Diagnostics by HPLC & LC-MS/MS). Data were statistically analysed through GraphPad prism ®7, and a p-value <0.05 was considered significant. Twenty-three males and 27 females of different breed, age and body weight were included. 24/50 (48%) dogs were diagnosed as AKI, while 13/50 (26%) were diagnosed as AKI/CKD. There was no statistically significant difference between pre and post treatment homocysteine values in AKI and AKI/CKD dogs. Mean post-treatment homocysteine concentrations showed a non significant trend to reduce, compared to pre-treatment concentrations. No statistically significant difference in homocysteine concentration was found between AKI and AKI/CKD. No statistically significant correlation between plasma homocysteine and creatinine was found. No differences were also found in homocysteine concentration between survived and not survived dogs. In conclusion homocysteine seem not to change between AKI and AKI/CKD dogs, and not to be significantly affected by the haemodialysis treatment. Further studies with larger number of dogs and complete cardiological evaluation should be encouraged.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
